Symbols

ATOS

Atossa Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 1

Bearish signal 1

Consensus Rating "Strong Buy"

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ATOS

Atossa Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions

Industry

Pharmaceutical

Established Date

04/30/2009

Listing Date

11/08/2012

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.atossatherapeutics.com

Security Type

Common stock

Office address

10202 5th Avenue NE, Suite 200, Seattle, WA 98125

Business

Introduction

Atossa Therapeutics, Inc., was incorporated in Delaware on April 30, 2009. They are a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines in the areas of significant unmet medical needs in oncology and infectious diseases, currently focusing on breast cancer, other breast conditions and COVID 19. The drug they are developing to treat breast cancer and other breast diseases is Endoxifen, which is mainly developed in two cases: one is to reduce tumor cell activity in breast cancer patients during the "window of opportunity" between breast cancer diagnosis and surgery; the other is suitable for women with dense breast tissue to reduce density. The two COVID 19 drugs they are developing are AT-H201, which is used to improve lung function in moderately to severely hospitalized COVID 19 patients by inhalation; and AT-301, a nasal spray for COVID 19 patients to use at home. Their business strategy is to advance their projects through clinical research, including partners, and opportunistically add projects in areas of unmet medical need through acquisitions, collaborations or in-house development.

Company Financials

EPS

ATOS has released its 2025 Q3 earnings. EPS was reported at -0.07, versus the expected -0.07, meeting expectations. The chart below visualizes how ATOS has performed over recent quarters, highlighting trends in earnings surprises.